Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Paratek Pharmaceuticals stock

Learn how to easily invest in Paratek Pharmaceuticals stock.

Paratek Pharmaceuticals Inc is a biotechnology business based in the US. Paratek Pharmaceuticals shares (PRTK) are listed on the NASDAQ and all prices are listed in US Dollars. Paratek Pharmaceuticals employs 207 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Paratek Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRTK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Paratek Pharmaceuticals stock price (NASDAQ: PRTK)

Use our graph to track the performance of PRTK stocks over time.

Paratek Pharmaceuticals shares at a glance

Information last updated 2022-07-03.
Latest market close$1.96
52-week range$1.60 - $7.02
50-day moving average $2.04
200-day moving average $3.64
Wall St. target price$18.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.18

Buy Paratek Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Paratek Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Paratek Pharmaceuticals price performance over time

Historical closes compared with the close of $1.96 from 2022-07-01

1 week (2022-06-27) -4.85%
1 month (2022-06-01) 4.26%
3 months (2022-04-01) -33.33%
6 months (2021-12-31) N/A
1 year (2021-07-02) -71.76%
2 years (2020-07-02) -61.94%
3 years (2019-07-03) 4
5 years (2017-07-03) 24.2

Paratek Pharmaceuticals financials

Revenue TTM $138.6 million
Gross profit TTM $78.3 million
Return on assets TTM -15.41%
Return on equity TTM 0%
Profit margin -42.32%
Book value $-0.42
Market capitalisation $106.8 million

TTM: trailing 12 months

Paratek Pharmaceuticals share dividends

We're not expecting Paratek Pharmaceuticals to pay a dividend over the next 12 months.

Have Paratek Pharmaceuticals's shares ever split?

Paratek Pharmaceuticals's shares were split on a 1:12 basis on 30 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Paratek Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Paratek Pharmaceuticals shares which in turn could have impacted Paratek Pharmaceuticals's share price.

Paratek Pharmaceuticals share price volatility

Over the last 12 months, Paratek Pharmaceuticals's shares have ranged in value from as little as $1.6 up to $7.02. A popular way to gauge a stock's volatility is its "beta".

PRTK.US volatility(beta: 1.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Paratek Pharmaceuticals's is 1.5749. This would suggest that Paratek Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Paratek Pharmaceuticals overview

Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co. , Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Paratek Pharmaceuticals is owned by insiders or institutions?
Currently 16.583% of Paratek Pharmaceuticals shares are held by insiders and 53.725% by institutions.
How many people work for Paratek Pharmaceuticals?
Latest data suggests 207 work at Paratek Pharmaceuticals.
When does the fiscal year end for Paratek Pharmaceuticals?
Paratek Pharmaceuticals's fiscal year ends in December.
Where is Paratek Pharmaceuticals based?
Paratek Pharmaceuticals's address is: 75 Park Plaza, Boston, MA, United States, 02116
What is Paratek Pharmaceuticals's ISIN number?
Paratek Pharmaceuticals's international securities identification number is: US6993743029
What is Paratek Pharmaceuticals's CUSIP number?
Paratek Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 66987B103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site